Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage gene editing company whose news flow centers on the development of CRISPR-based therapies. Company announcements frequently highlight progress in its in vivo programs, including nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis and lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). Investors following NTLA news can see updates on clinical trial data, regulatory interactions and platform developments that shape the company’s pipeline.
Recent Intellia press releases and SEC-furnished materials describe longer-term Phase 1 and Phase 1/2 data for nex-z and lonvo-z, pooled analyses of patient outcomes, and details from global Phase 3 trials such as MAGNITUDE, MAGNITUDE-2 and HAELO. News items also cover events such as temporary pauses in patient dosing, FDA clinical holds on Phase 3 nex-z trials, and subsequent company plans to work with regulators. These disclosures provide insight into both the potential and the risks associated with Intellia’s CRISPR-based candidates.
Beyond clinical results, NTLA news includes quarterly financial updates, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor presentations at major healthcare conferences. Together, these items give a view into Intellia’s operational progress, capital position and strategic priorities as it advances gene editing therapies for serious diseases like ATTR amyloidosis and HAE.
This news page aggregates Intellia’s latest press releases and related market-moving information in one place, allowing readers to review clinical milestones, regulatory developments and corporate updates linked to the NTLA stock.
Intellia Therapeutics (NASDAQ:NTLA) announced the successful closing of a public offering of 5,513,699 shares at $36.50 per share, raising approximately $201 million before deductions. This includes the full exercise of the underwriters' option for an additional 719,178 shares. Goldman Sachs, Jefferies, and SVB Leerink were the joint book-running managers. The offering was conducted under a previously filed shelf registration statement with the SEC. The funds are expected to enhance Intellia's genome editing technology aimed at developing curative therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) announced a public offering of 4,794,521 shares at $36.50 each, aiming to raise approximately $175 million before expenses. The underwriters, including Goldman Sachs, Jefferies, and SVB Leerink, hold a 30-day option to purchase an additional 719,178 shares. The offering is set to close around December 4, 2020. The shares are being offered under a previously filed shelf registration statement. This financing aims to support Intellia's development of CRISPR-based therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) announced a public offering of $150 million in common stock, with an option for underwriters to purchase an additional 15% of shares. The offering is underwritten by Goldman Sachs, Jefferies, and SVB Leerink and is subject to market conditions. Shares are being sold under a previously filed shelf registration with the SEC. The company focuses on developing CRISPR/Cas9-based therapeutics. The completion of the offering depends on various factors, and the offering's size and terms may change.
Intellia Therapeutics (NASDAQ: NTLA) has received a grant from the Bill & Melinda Gates Foundation to develop non-viral treatments for sickle cell disease (SCD) using its CRISPR/Cas9 genome editing technology. This initiative aims to create safe and scalable solutions for SCD over the next 7-10 years, particularly addressing the disease's impact in developing countries. The funding will support preclinical validation of Intellia’s non-viral delivery systems for genome editing. SCD affects millions globally, with a high incidence in sub-Saharan Africa and India.
Intellia Therapeutics (NASDAQ:NTLA) announced the treatment of the first patient with NTLA-2001, a revolutionary potential therapy for transthyretin amyloidosis (ATTR). This groundbreaking single-course therapy utilizes CRISPR technology to potentially halt and reverse disease progression. The Phase 1 study focuses on hereditary ATTR with polyneuropathy, aiming for future trials across broader ATTR patient groups. Intellia's robust plans include rapid movement to pivotal studies, establishing NTLA-2001 as a leading candidate in curative treatments for ATTR.
Intellia Therapeutics (NTLA) announced significant progress in its clinical programs, notably the initiation of a Phase 1 trial for NTLA-2001, targeting transthyretin amyloidosis (ATTR), with patient dosing expected by year-end 2020. The company also aims to submit IND applications for NTLA-5001 (acute myeloid leukemia) in 1H 2021, and NTLA-2002 (hereditary angioedema) in 2H 2021. Financially, Intellia ended Q3 2020 with $407.9 million in cash, marking a healthy increase from the previous year, despite a net loss of $27.8 million. Collaboration revenue rose significantly, driven by the Regeneron partnership.
Intellia Therapeutics (NASDAQ:NTLA) will present its Q3 2020 financial results and operational highlights on November 5, 2020, at 8 a.m. ET. Interested participants can join the call by dialing 1-877-317-6789 in the U.S. or 1-412-317-6789 internationally. A replay will be available post-call on the company's website from 12 p.m. ET the same day. Intellia is focused on developing curative therapeutics using CRISPR/Cas9 technology, aiming to revolutionize medicine by permanently editing disease-related genes with a single treatment.
Intellia Therapeutics (NASDAQ: NTLA) announced the authorization of its Clinical Trial Application to commence a Phase 1 study of NTLA-2001, targeting hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). This therapy, potentially the first curative treatment for ATTR, utilizes in vivo CRISPR/Cas9 technology. The trial aims to assess safety, pharmacokinetics, and efficacy, with expectations to dose the first patient by the end of 2020. Intellia plans to expand the study after determining the optimal dose and further regulatory applications in other countries.
Intellia Therapeutics' co-founder, Dr. Jennifer Doudna, has been awarded the 2020 Nobel Prize in Chemistry for her role in developing the CRISPR/Cas9 genome editing technology, alongside Dr. Emmanuelle Charpentier. This milestone marks the first instance of two women jointly winning this accolade in Chemistry. Intellia’s leadership highlighted the transformative potential of CRISPR/Cas9 in addressing genetic diseases and cancer. The company underscores its commitment to utilizing this groundbreaking tool to develop enduring therapeutic solutions for complex health conditions.
Intellia Therapeutics (NASDAQ: NTLA) has appointed John F. Crowley to its Board of Directors, bringing extensive biotech experience, particularly in rare diseases. Crowley, CEO of Amicus Therapeutics, has a strong track record in transitioning programs from preclinical to clinical stages. His insights as a parent advocate for Pompe disease will be valuable as Intellia embarks on its first clinical trial this year. Meanwhile, Perry Karsen will step down from the board effective December 31, 2020, after five years of significant contributions to the company's growth.